Published in Clin Transplant on February 13, 2013
Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell (2007) 14.87
Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med (2009) 6.72
Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA (2009) 3.83
Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol (2002) 3.34
The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant (2010) 2.59
A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med (2008) 2.26
Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. Am J Transplant (2003) 2.18
Temporary intraoperative porto-caval shunt: useless or beneficial in piggy back liver transplantation? Transpl Int (2012) 2.17
A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med (2005) 2.13
Loss of liver transplant surgeons into alternate career paths. Transpl Int (2014) 2.04
Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol (2002) 2.02
Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc Natl Acad Sci U S A (2009) 1.95
Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients. Nephrol Dial Transplant (2010) 1.59
Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J Immunol (2005) 1.58
The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol (2004) 1.54
Impaired glucose tolerance in rats fed low-carbohydrate, high-fat diets. Am J Physiol Endocrinol Metab (2013) 1.54
PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol (2007) 1.51
The emerging role of T cell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model. J Clin Invest (2008) 1.50
Sirolimus impairs gonadal function in heart transplant recipients. Am J Transplant (2004) 1.50
Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy. Transplantation (2003) 1.48
Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg (2011) 1.44
Heart transplantation: an approach to treating primary cardiac sarcoma? J Heart Lung Transplant (2002) 1.40
Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation (2004) 1.40
Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev (2007) 1.38
Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res (2008) 1.35
Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit (2006) 1.30
Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res (2004) 1.28
Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res (2007) 1.21
Specificity of CD4+CD25+ regulatory T cell function in alloimmunity. J Immunol (2006) 1.19
Vascular endothelial growth factor in esophageal cancer. J Surg Oncol (2004) 1.19
GFP-transfected tumor cells are useful in examining early metastasis in vivo, but immune reaction precludes long-term tumor development studies in immunocompetent mice. Clin Exp Metastasis (2003) 1.19
Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation (2003) 1.14
The contribution of B cells to renal interstitial inflammation. Am J Pathol (2007) 1.14
The intrinsic renal compartment syndrome: new perspectives in kidney transplantation. Transplantation (2010) 1.10
Detection and identification of tumor-associated protein variants in human hepatocellular carcinomas. Hepatology (2004) 1.09
The chemokine receptor 5 Delta32 mutation is associated with increased renal survival in patients with IgA nephropathy. Kidney Int (2005) 1.07
Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation. J Am Soc Nephrol (2011) 1.06
Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: comparable survival and recurrence. Liver Transpl (2012) 1.06
Long-term outcome and prognostic factors of patients with hilar cholangiocarcinoma. World J Gastroenterol (2007) 1.03
Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept? Am J Kidney Dis (2006) 1.03
Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy. Clin Cancer Res (2004) 1.02
Umbilical cord tissue-derived mesenchymal stem cells grow best under GMP-compliant culture conditions and maintain their phenotypic and functional properties. J Immunol Methods (2010) 1.02
RANTES gene polymorphisms predict all-cause and cardiac mortality in type 2 diabetes mellitus hemodialysis patients. Atherosclerosis (2005) 1.02
Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin Cancer Res (2004) 1.01
Extracorporeal membrane oxygenation in 108 patients with low cardiac output – a single-center experience. Int J Artif Organs (2011) 1.00
The TIM-1:TIM-4 pathway enhances renal ischemia-reperfusion injury. J Am Soc Nephrol (2011) 1.00
Ephrin-B2 overexpression enhances integrin-mediated ECM-attachment and migration of B16 melanoma cells. Int J Oncol (2005) 0.99
Genetically engineered stem cells for therapeutic gene delivery. Curr Gene Ther (2007) 0.99
Is it time for a cardiac allocation score? First results from the Eurotransplant pilot study on a survival benefit-based heart allocation. J Heart Lung Transplant (2013) 0.99
Impact of human herpesvirus-6 after haematopoietic stem cell transplantation. Br J Haematol (2005) 0.97
The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1. J Cell Biochem (2007) 0.97
Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial. Transplantation (2010) 0.96
Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function. Circulation (2004) 0.96
A Monocyte chemoattractant protein-1 (MCP-1) polymorphism and outcome after renal transplantation. J Am Soc Nephrol (2002) 0.95
Evaluation of the lung allocation score in highly urgent and urgent lung transplant candidates in Eurotransplant. J Heart Lung Transplant (2010) 0.95
Acute interstitial nephritis associated with moxifloxacin use. Clin Ther (2005) 0.94
Gender does matter: gender-specific outcome analysis of 67,855 heart transplants. Thorac Cardiovasc Surg (2012) 0.94
A novel clinically relevant approach to tip the balance toward regulation in stringent transplant model. Transplantation (2010) 0.94
Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients. Transpl Int (2013) 0.94
HLA-DR matching improves survival after heart transplantation: is it time to change allocation policies? J Heart Lung Transplant (2006) 0.93
Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study. Transpl Int (2014) 0.92
Preventing cardiac allograft vasculopathy: long-term beneficial effects of mycophenolate mofetil. J Heart Lung Transplant (2006) 0.91
Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J Heart Lung Transplant (2004) 0.91
Donor scoring system for heart transplantation and the impact on patient survival. J Heart Lung Transplant (2011) 0.91
Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. HPB (Oxford) (2010) 0.90
A novel alloantigen-specific CD8+PD1+ regulatory T cell induced by ICOS-B7h blockade in vivo. J Immunol (2007) 0.90
Mapping of conformational epitopes on human proteinase 3, the autoantigen of Wegener's granulomatosis. J Immunol (2010) 0.90
Defining an extended criteria donor lung: an empirical approach based on the Eurotransplant experience. Transpl Int (2010) 0.89
Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer. Angiogenesis (2007) 0.89
Treatment of Crigler-Najjar type 1 disease: relevance of early liver transplantation. J Pediatr Surg (2003) 0.89
Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally induced chronic colitis. Int J Colorectal Dis (2005) 0.88
Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy. Kidney Int (2005) 0.88
Long-term outcomes after 1000 heart transplantations in six different eras of innovation in a single center. Transpl Int (2009) 0.86
Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. Anticancer Drugs (2007) 0.86
Lymphotoxin-beta receptor immune interaction promotes tumor growth by inducing angiogenesis. Cancer Res (2002) 0.85
Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation. Transpl Int (2012) 0.85
Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation. J Heart Lung Transplant (2008) 0.84
A comprehensive genotype-phenotype interaction of different Toll-like receptor variations in a renal transplant cohort. Clin Sci (Lond) (2010) 0.84
The impact of polymorphisms in chemokine and chemokine receptors on outcomes in liver transplantation. Am J Transplant (2002) 0.84
Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? a systematic review and meta-analysis. Transplantation (2012) 0.84
Acute liver failure after administration of herbal tranquilizer kava-kava (Piper methysticum). J Clin Psychiatry (2003) 0.84
Preseeding with autologous fibroblasts improves endothelialization of glutaraldehyde-fixed porcine aortic valves. J Thorac Cardiovasc Surg (2003) 0.83
Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure. Transplantation (2009) 0.83
Impact of simvastatin therapy after heart transplantation an 11-year prospective evaluation. Herz (2005) 0.83
Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. J Heart Lung Transplant (2009) 0.83
Vitamin C plasma level and response to erythropoietin in patients on maintenance haemodialysis. Nephrol Dial Transplant (2004) 0.82
Prolonged graft survival in older recipient mice is determined by impaired effector T-cell but intact regulatory T-cell responses. PLoS One (2010) 0.81
Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation. Transplantation (2006) 0.81
Gender-based analysis of outcome after heart transplantation. Exp Clin Transplant (2012) 0.81
Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results. J Heart Lung Transplant (2013) 0.81
Pre-transplant predictors of cerebrovascular events after kidney transplantation. Nephrol Dial Transplant (2007) 0.81